Latest News & Updates
Breaking News
14 minutes ago
Simantini Singh Deo
Other trending news you may like to read
MAIA Biotechnology Doses First Patient In THIO-104 Phase 3 Trial Testing Ateganosine As A Third-Line Treatment For Advanced NSCLC
MAIA doses the first patient in its THIO-104 Phase 3 trial evaluating ateganosine plus CPI for advanced NSCLC, marking a key step toward potential FDA approval.
Simantini Singh Deo
Abeona Therapeutics Activates UTMB Galveston As New Qualified Treatment Center To Administer FDA-Approved ZEVASKYN Gene Therapy For RDEB Patients
UTMB becomes a Qualified Treatment Center for ZEVASKYN, expanding access to the FDA-approved gene therapy for patients with recessive dystrophic epidermolysis bullosa.
Simantini Singh Deo
Kymera Therapeutics Receives FDA Fast Track Designation For KT-621, Its First-In-Class Oral STAT6 Degrader For Moderate To Severe Atopic Dermatitis
FDA grants Fast Track status to Kymera’s KT-621, a first-in-class oral STAT6 degrader aimed at transforming treatment for moderate to severe atopic dermatitis.
Simantini Singh Deo
Centessa Pharmaceuticals Appoints Mario Accardi, PhD, CEO, Highlighting Focus On Orexin-Based Treatments For Neurological And Neuropsychiatric Disorders
Centessa appoints Mario Accardi as CEO to lead its orexin-focused neuroscience strategy, advancing OX2R agonist programs toward major 2026 milestones.
Simantini Singh Deo
